MELANOMA BRIDGE 2018
Royal Continental Hotel, Naples, Italy
November 29th - December 1st, 2018
Presidents

Paolo A. Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Corrado Caracò
Chief of advanced melanoma treatment, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Igor Puzanov
Professor of Medicine, Director of Early Phase Clinical Trials Program, Melanoma Section Chief and Co-Leader of Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
Scientific Board

Sanjiv Agarwala
Chief of Medical oncology and Hematology, St. Luke’s University Hospital and Temple University, Bethlehem, Pennsylvania

Paolo A. Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Carlo Bifulco
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon

Lisa H. Butterfield
Professor of Medicine, Surgery, Immunology and Clinical and Translational Science at the University of Pittsburgh and Director of the Immunologic Monitoring and Cellular Products Laboratory (IMCPL) at the UPMC Hillman Cancer Center, Pittsburgh, USA

Corrado Caracò
Chief of advanced melanoma treatment, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Reinhard Dummer
Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

Bernard A. Fox
Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon

Jerome Galon
Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

Claus Garbe
University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany

Giuseppe Masucci
Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Michael Postow
Memorial Sloane Kettering Cancer Center, New York, New York

Igor Puzanov
Professor of Medicine, Director of Early Phase Clinical Trials Program, Melanoma Section Chief and Co-Leader of Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA

Magdalena Thurin
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland
For information please contact info@melanomabridge.org